Pharmacoeconomic review report : Nitisinone (Orfadin) (Sobi Canada Inc.)

Pharmacoeconomic review report Nitisinone (Orfadin) (Sobi Canada Inc.)

Nitisinone (Orfadin) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT- 1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules for oral administration. The submitted price of nitisinon...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Materias:
Drugs > Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268806719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Summary of Key Outcomes
  • Appendix 3. Additional Information
  • Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug
  • Appendix 5. Reviewer Worksheets
  • References.

Ejemplares similares